Akebia Therapeutics
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Akebia Therapeutics's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 33% to $194,623,000. The net income raised on -$51,925,000 and profit margin reached -27%. Total operating expenses were $166,730,000.
Profit Margin
| 2014 | 0 | -37.03M | |
|---|---|---|---|
| 2015 | 0 | -60.71M | |
| 2016 | 1.53M | -135.74M | -8843.45% |
| 2017 | 177.98M | -76.91M | -43.21% |
| 2018 | 207.74M | -171.90M | -82.75% |
| 2019 | 335.00M | -279.65M | -83.48% |
| 2020 | 295.30M | -349.86M | -118.48% |
| 2021 | 213.57M | -244.87M | -114.65% |
| 2022 | 292.60M | -106.00M | -36.23% |
| 2023 | 194.62M | -51.92M | -26.68% |
AKBA Income Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||
Revenue | 194.62M | 292.60M | 213.57M | 295.30M | 335.00M | 207.74M | 177.98M | 1.53M | 0 | 0 |
Cost of revenue | 74.14M | 84.79M | 153.39M | 295.90M | 145.33M | 7.68M | 617K | 115.78M | 96K | 23.26M |
Gross profit | 120.47M | 207.80M | 60.18M | -601K | 189.66M | 200.05M | 177.36M | -114.25M | -96K | -23.26M |
Operating exp. | ||||||||||
Research and development | 63.07M | 129.11M | 147.85M | 218.48M | 322.96M | 291.06M | 230.89M | 115.78M | 43.01M | 25.39M |
Selling and marketing | 100.23M | -3.17M | 174.16M | 153.94M | 149.45M | 87.06M | 0 | 0 | 0 | 0 |
Total operating expenses | 166.73M | 270.98M | 325.50M | 375.84M | 475.95M | 378.19M | 257.90M | 137.99M | 61.51M | 37.94M |
Operating income | -46.25M | -63.18M | -265.31M | -376.44M | -286.28M | -178.13M | -79.91M | -136.46M | -61.51M | -37.94M |
Other income (expenses), net | -5.66M | -29.38M | -17.52M | -5.63M | -2K | 6.23M | 3.00M | -188K | 497K | 906K |
Income before tax | -51.92M | -92.56M | -282.84M | -383.45M | -286.29M | -171.90M | -76.91M | -135.74M | -60.71M | -37.03M |
Income tax expense | 0 | 13.44M | -37.97M | -33.59M | -6.63M | -28.33M | -2.79M | -901K | -510K | -206K |
Net income | -51.92M | -106.00M | -244.87M | -349.86M | -279.65M | -171.90M | -76.91M | -135.74M | -60.71M | -37.03M |
Earnings per share | ||||||||||
Basic EPS | -0.28 | -0.58 | -1.48 | -2.53 | -2.36 | -1.47 | -1.77 | -3.6 | -2.29 | -2.4 |
Diluted EPS | -0.28 | -0.58 | -1.48 | -2.53 | -2.36 | -1.47 | -1.77 | -3.6 | -2.29 | -2.4 |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |